Medical Pharmacology: Antiviral Drug Practice Questions
Click on the correct answer.
Abacavir (Ziagen):
Synthetic purine (guanine analogue).
Approved in combination with other antivirals for treatment of HIV-1 infection.
Both
Neither
Abacavir formulations:
Coformulated with zidovudine and lamivudine
Coformulated with lamivudine
Coformulated with lamivudine and dolutegravir
A & B
B & C
A & C
A, B & C
Abacavir pharmacokinetics:
Poorly absorbed when given orally
Absorption reduced in the presence of food.
Both
Neither
Half-life for abacavir is about 1.5 hours.
True
False
Abacavir disposition:
Excreted unchanged by the kidney
Undergoes liver glucuronidation and carboxylation
Abacavir dosage may be appropriately reduced if the patient exhibits mild liver impairment.
True
False
If the patient exhibits moderate or severe hepatic dysfunction, abacavir
administration would not be recommended.
True
False
Abacavir is one of the nucleoside/nucleotide reverse transcriptase inhibitors (NRTIs) that is recommended for use in the pregnant patient.
True
False
Activation of abacavir:
Multiple phosphorylation steps
Active form is carbovir 5'-triphosphate
Both
Neither
Abacavir is a strong inhibitor of cytochrome P450's and as such is likely to be involved in drug-drug interactions.
True
False
Most important adverse effect associated with abacavir administration: a potentially fatal hypersensitivity reaction associated with abdominal pain, fever, and other gastrointestinal symptoms.
True
False
Ethanol, possibly due tocompetition with abacavir for alcohol dehydrogenase, has at high doses the potential of prolonging abacavir half-life.
If you wish to return to the Table of Contents
in ENGLISH, press the RETURN button above.
Otherwise, if the text is NOT displayed in
English and you are ready to leave this page,
Press here
to return to the Table of Contents
Source Material:
Acosta EP Chapter 62 Antiviral Agents (Nonretroviral)
in Goodman & Gilman's: The Pharmcological
Basis of Therapeutics, 14e, (Brunton LL Knollmann BC eds) McGraw-Hill Education, 2023.
Safrin S Chapter 49 Antiviral Agents in
Basic & Clinical Pharmacology (Katzung BG, Editor;
Vanderah TW, Associate editor) 15e McGraw Hill 2021.
Li JZ Coen DM Chapter 38 Pharmacology of
Viral Infections in Principles of Pharmacology:
The Pathophysiologic Basis of Drug Therapy 4e (Golan DE
Armstong EJ Armstrong AW, eds) Wolters Kluwer 2017.
Waller DB Sampson AP Section 11
Chemotherapy in Medical Pharmacology & Therapeutics
Elsevier 2018.
Burchum JR Rosenthal LD Chapter 97
Antiviral Agents I: Drugs for Non-HIV Viral Infections
in Lehne's Pharmacology for Nursing Care Elsevier 2022.
Waller DB Sampson AP Section 11: Chapter
51
Chemotherapy of infections in Medical Pharmacology & Therapeutics
Elsevier 2018.
Benavides S Bahal O'Mara N Nahata MC
Chapter 79 Viral Infections in Applied Therapeutics:
The Clinical Use of Drugs (Zeind C, Carvalho MG Cheng JW
Zaiken K Lapointe T, eds) Wolters Kluwer, 2024.
Davanathan AS Symonds AE Adams JL
Cottrell ML Chapter 76 Pharmacotherapy of Human
Immunodeficiency Virus Infection
in Applied
Therapeutics: The Clinical Use of Drugs (Zeind C, Carvalho MG Cheng JW
Zaiken K Lapointe T, eds) Wolters Kluwer, 2024.
Flexner CW Chapter 64 Antiretroviral
Agents and Treatment of HIV Infection
in Goodman &
Gilman's: The Pharmcological
Basis of Therapeutics, 14e, (Brunton LL Knollmann BC eds) McGraw-Hill Education, 2023.
Burchum JR Rosenthal LD Chapter
98
Antiviral Agents II: Drugs for HIV Infection and Related
Opportunistic Infections
in Lehne's Pharmacology for Nursing Care Elsevier 2022.
